Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06776783Phase 3Recruiting

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

Role: lead

NCT03969992Phase 2Completed

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

Role: lead

NCT03122730Phase 2Completed

VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

Role: lead

NCT04452669Phase 2Completed

VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

Role: lead

All 4 trials loaded